Abstract Number: 0897 • ACR Convergence 2020
Temporal Achievement of Clinical Response and Inactive Disease Status in Patients with Axial Spondyloarthritis Treated with Etanercept
Background/Purpose: Treatment with etanercept (ETN) is effective and well tolerated in patients with axial spondyloarthritis (AS), but the time frames within which patients tend to…Abstract Number: 1399 • ACR Convergence 2020
Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Background/Purpose: Inhibition of TNFα has emerged as an effective therapeutic approach for many autoimmune/inflammatory diseases.While the efficacy and safety profile of the five FDA-approved TNFis…Abstract Number: 0710 • ACR Convergence 2020
Early Start of Biological Treatment in Juvenile Idiopathic Arthritis: Does a Therapeutic Window Exist in Real Life?
Background/Purpose: Data about when is the best moment to start BT in Juvenile Idiopathic Arthritis (JIA) patients and the impact of this prompt initiation are…Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…Abstract Number: 1406 • ACR Convergence 2020
LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Aberrant T cell regulation has been implicated in the process of inflammation in…Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…Abstract Number: 1045 • ACR Convergence 2020
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…Abstract Number: 1544 • ACR Convergence 2020
Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Background/Purpose: Rheumatoid Arthritis (RA) is a serious and potentially debilitating disease, but low disease activity and even clinical remission can be obtained if an effective…Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…Abstract Number: 1054 • ACR Convergence 2020
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…Abstract Number: 1605 • ACR Convergence 2020
Knowledge of Biosimilars and Perceptions of Biosimilar Naming Conventions in Clinical Practice
Background/Purpose: The market introduction of biosimilars has generated the need for novel biologic naming conventions, in part to support pharmacovigilance. We evaluated the familiarity of…Abstract Number: 0038 • ACR Convergence 2020
Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients – The Bioefficacy SpA Study
Background/Purpose: Axial Spondyloarthritis (AS) is amongst the most common forms of inflammatory arthritis. Widely used in the treatment of axSpA, adalimumab is an engineered antibody…Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…Abstract Number: 1191 • ACR Convergence 2020
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
ACR Meeting Abstracts